The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology

0504220 - FGÚ 2020 RIV GB eng J - Článek v odborném periodiku
Maletínská, L. - Popelová, A. - Železná, B. - Bencze, Michal - Kuneš, Jaroslav
The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology.
Journal of Endocrinology. Roč. 240, č. 2 (2019), R47-R72. ISSN 0022-0795. E-ISSN 1479-6805
Institucionální podpora: RVO:67985823
Klíčová slova: Alzheimer's disease pathology * experimental rodent models * leptin * anorexigenic neuropeptides
Obor OECD: Neurosciences (including psychophysiology
Impakt faktor: 4.041, rok: 2019
Způsob publikování: Open access
https://joe.bioscientifica.com/downloadpdf/journals/joe/240/2/JOE-18-0532.pdf

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the elderly population. Numerous epidemiological and experimental studies have demonstrated that patients who suffer from obesity or type 2 diabetes mellitus have a higher risk of cognitive dysfunction and AD. Several recent studies demonstrated that food intake lowering (anorexigenic) peptides have the potential to improve metabolic disorders and that they may also potentially be useful in the treatment of neurodegenerative diseases. In this review, the neuroprotective effects of anorexigenic peptides of both peripheral and central origins are discussed. Moreover, the role of leptin as a key modulator of energy homeostasis is discussed in relation to its interaction with anorexigenic peptides and their analogs in AD-like pathology. Although there is no perfect experimental model of human AD pathology, animal studies have already proven that anorexigenic peptides exhibit neuroprotective properties. This phenomenon is extremely important for the potential development of new drugs in view of the aging of the human population and of the significantly increasing incidence of AD.
Trvalý link: http://hdl.handle.net/11104/0295905